[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355711-105":59,"doc-detail-355711-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pan-cancer-analysis-reveals-the-prognostic-and-therapeutic-relevance-of-mex3a-with-a-focus-on-chromophobe-renal-cell-carcinoma","Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma","","Pan-cancer analysis investigates MEX3A, an RNA-binding protein involved in post-transcriptional regulation, and clarifies its function across cancers with emphasis on chromophobe renal cell carcinoma (chRCC). Using TCGA and related databases, the study evaluates MEX3A expression, prognostic value, immune associations, genomic alterations, and drug sensitivity, then validates key mechanisms in chRCC cell lines. Results show higher MEX3A predicts poor outcomes and weaker drug sensitivity, linking expression to immune infiltration, checkpoint molecules, tumor mutational burden, microsatellite instability, and oncogenic behavior.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-reveals-the-prognostic-and-therapeutic-relevance-of-mex3a-with-a-focus-on-chromophobe-renal-cell-carcinoma/355711/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-reveals-the-prognostic-and-therapeutic-relevance-of-mex3a-with-a-focus-on-chromophobe-renal-cell-carcinoma/355711.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is MEX3A and why is it studied in this research?","Question",{"text":112,"@type":113},"MEX3A is an RNA-binding protein implicated in post-transcriptional regulation. The study investigates its role across cancers, especially in chromophobe renal cell carcinoma (chRCC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data and approaches are used to analyze MEX3A in pan-cancer context?",{"text":117,"@type":113},"The analysis uses TCGA and related databases to assess MEX3A expression, prognostic significance, immune associations, genomic alterations, and drug sensitivity. Functional experiments are conducted in chRCC cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"How does MEX3A relate to prognosis, immune features, and drug sensitivity?",{"text":121,"@type":113},"MEX3A is upregulated in multiple cancers and is associated with poor prognosis. Its expression correlates with immune cell infiltration, immune checkpoint molecules, tumor mutational burden, and microsatellite instability, and high levels link to reduced drug sensitivity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355711,1790798079,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","TYPE Original Research PUBLISHED 29 April 2026  \nDOI 10.3389/fonc.2026.1802679  \nOPEN ACCESS  \nEDITED BY  \nLele Song,  \nEighth Medical Center of the General Hospital of the Chinese People’s Liberation Army, China  \nREVIEWED BY  \nRajeev Mishra,  \nChhatrapati Shahu Ji Maharaj University, India  \nYing Shi,  \nHuazhong University of Science and Technology, China  \n*CORRESPONDENCE  \nYi Feng  \n [hmu18235277020@163.com](hmu18235277020@163.com)[ ](hmu18235277020@163.com)Tao Li  \n [baobudong@126.com](baobudong@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 03 February 2026  \nREVISED 04 April 2026  \nACCEPTED 15 April 2026  \nPUBLISHED 29 April 2026  \nCITATION  \nWang S, Zhang J, Zheng M, Feng Y and Li T (2026) Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus onchromophobe renal cell carcinoma. Front. Oncol. 16:1802679 .  \ndoi: 10.3389/fonc.2026.1802679  \nCOPYRIGHT  \n© 2026 Wang, Zhang, Zheng, Feng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe  \nrenal cell carcinoma  \nShuang Wang 1†, Jiejun Zhang 2†, Mengyu Zheng 3†, Yi Feng 4* and Tao Li 5*  \n1 Nursing Department, The Fourth Afﬁliated Hospital of Harbin Medical University, Harbin, China,  \n2 Neurology Department, Yanda Hospital, Langfang, China, 3 Department of Cardiology, Kaifeng Central Hospital, Kaifeng, China, 4 Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin, China, 5 Department of Cardiology, The Fourth Afﬁliated Hospital of Harbin Medical University, Harbin, China  \nBackground: MEX3A is an RNA-binding protein implicated in post-transcriptional regulation; however, its role across cancers, particularly in chromophobe renal cell carcinoma (chRCC), remains unclear.  \nMethods: We performed a comprehensive pan-cancer analysis using TCGA and related databases to evaluate MEX3A expression, prognostic signiﬁcance, immune associations, genomic alterations, and drug sensitivity. Functional experiments were conducted in chRCC cell lines.  \nResults: MEX3A was signiﬁcantly upregulated in multiple cancers and was associated with poor prognosis. Its expression correlated with immune cell inﬁltration, immune checkpoint molecules, tumor mutational burden, and microsatellite instability. High MEX3A expression was linked to reduced drug sensitivity. Functional assays conﬁrmed its oncogenic role in chRCC. Conclusion: MEX3A serves as a potential prognostic biomarker and therapeutic target in chRCC and may play a critical role in tumor progression and immune regulation.  \nKEYWORDS  \nchRCC, MEX3A, drug sensitivity, immune regulation, genomic regulation, prognostic biomarker  \n1 Introduction  \nCancer continues to be a major cause of human mortality globally. Projections indicate that by 2040, there will be approximately 29.9 million cancer cases and 15.3 million deaths, underscoring the urgency to strengthen cancer care systems (1) . Importantly, it is not a uniform disease but a heterogeneous ensemble of over 100 distinct malignancies, each with unique clinical features, genetic architectures, and therapeutic sensitivities (2) . This complexity demands innovative strategies to decode its underlying mechanisms. Historically, cancers have been classiﬁed by tissue of origin, a framework that has long guided diagnosis and treatment. However, this approach fails to capture the molecular  \nFrontiers in Oncology 01 [frontiersin.org](fr","cbCaiaErMYLrAgNU","https://ap.wps.com/l/cbCaiaErMYLrAgNU","pdf",18933069,14,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Key keywords\n# Introduction","[{\"question\":\"What is MEX3A and why is it studied in this research?\",\"answer\":\"MEX3A is an RNA-binding protein implicated in post-transcriptional regulation. The study investigates its role across cancers, especially in chromophobe renal cell carcinoma (chRCC).\"},{\"question\":\"What data and approaches are used to analyze MEX3A in pan-cancer context?\",\"answer\":\"The analysis uses TCGA and related databases to assess MEX3A expression, prognostic significance, immune associations, genomic alterations, and drug sensitivity. Functional experiments are conducted in chRCC cell lines.\"},{\"question\":\"How does MEX3A relate to prognosis, immune features, and drug sensitivity?\",\"answer\":\"MEX3A is upregulated in multiple cancers and is associated with poor prognosis. Its expression correlates with immune cell infiltration, immune checkpoint molecules, tumor mutational burden, and microsatellite instability, and high levels link to reduced drug sensitivity.\"}]","Pan-cancer analysis reveals the prognostic and therapeutic relevance of MEX3A with a focus on chromophobe renal cell carcinoma | PDF",1790120603,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8f3d977932dc17b69f9b73ae0398486.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba20335104c3cfdcf80314e6ecb79419.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ff05215cfd12ccd99268e362f384b95.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e44c88f4f4eb2c3f8ab7bf260189006.webp",980,1385]